4//SEC Filing
INTERCEPT PHARMACEUTICALS INC 4
Accession 0001144204-15-005703
CIK 0001270073operating
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 9:01 PM ET
Size
16.7 KB
Accession
0001144204-15-005703
Insider Transaction Report
Form 4
Regan Daniel Paul
Chief Commerical Officer
Transactions
- Sale
Common Stock
2015-01-30$208.08/sh−200$41,616→ 1,264 total - Exercise/Conversion
Common Stock
2015-01-30$37.69/sh+9,847$371,133→ 11,111 total - Sale
Common Stock
2015-01-30$200.07/sh−6,847$1,369,859→ 4,264 total - Sale
Common Stock
2015-01-30$201.50/sh−1,207$243,213→ 3,057 total - Exercise/Conversion
Option to Purchase Common Stock
2015-01-30−9,847→ 92,028 totalExercise: $37.69Exp: 2023-03-04→ Common Stock (9,847 underlying) - Sale
Common Stock
2015-01-30$202.49/sh−793$160,577→ 2,264 total - Sale
Common Stock
2015-01-30$205.87/sh−800$164,698→ 1,464 total
Footnotes (6)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 14, 2014.
- [F2]The remaining shares underlying this option vest on a pro rata monthly basis through March 4, 2017, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
- [F3]This transaction was executed in multiple trades at prices ranging from $200.0000 to $200.8100. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $201.0100 to $202.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $202.0100 to $203.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This transaction was executed in multiple trades at prices ranging from $205.5000 to $206.2450. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
INTERCEPT PHARMACEUTICALS INC
CIK 0001270073
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001270073
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 9:01 PM ET
- Size
- 16.7 KB